Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
These 27 stocks can give you a more diversified portfolio than the S&P 500 -- and that's a key advantage right now
12:30pm, Saturday, 22'nd Oct 2022 MarketWatch
The Natixis Vaughan Nelson Select Fund and its ETF counterpart are more diversified than the S&P 500 because of factor analysis.
2 Powerhouse Stocks That Could Go Parabolic
10:00am, Saturday, 22'nd Oct 2022
These stocks could take you by surprise.
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
08:45am, Saturday, 22'nd Oct 2022
Procrastination could be problematic with these three bargain stocks.
S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength
08:00am, Saturday, 22'nd Oct 2022
S&P 500 giant Vertex and Cheniere Energy, the largest U.S. liquefied natural gas producer, are setting up bullishly in the bear market. The post S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Str
These 3 Stocks Are Winning the Bear Market -- Here's How
01:30pm, Friday, 21'st Oct 2022 The Motley Fool
Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
09:55am, Friday, 21'st Oct 2022 The Motley Fool
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.
This Beaten-Down ETF Is Still a Screaming Bear-Market Buy
05:55am, Friday, 21'st Oct 2022
Investors wanting to profit from a potential biotech sector bounce should love this exchange-traded fund.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.64%: What You Should Know
09:50pm, Thursday, 20'th Oct 2022 Zacks Investment Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $290.16, marking a -0.64% move from the previous day.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
02:01pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos
04:38pm, Wednesday, 19'th Oct 2022 Zacks Investment Research
Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.
2 Unstoppable Stocks That Are Beating the Bear Market
01:07pm, Wednesday, 19'th Oct 2022 The Motley Fool
Is it too late to buy these stocks or are their shares likely to continue rising?
2 Unstoppable Stocks That Are Beating the Bear Market
09:07am, Wednesday, 19'th Oct 2022
Is it too late to buy these stocks or are their shares likely to continue rising?
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 Update
07:10am, Wednesday, 19'th Oct 2022 Seeking Alpha
ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. Click to see the firm's trades for Q3 2022.
2 Top Healthcare Stocks to Buy for the Long Haul
02:00pm, Tuesday, 18'th Oct 2022 The Motley Fool
These biotech companies have a long ramp of revenue growth ahead.
